Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape by Obeng‐gyasi, Samilia et al.
This is the author manuscript accepted for publication and has undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/CNCR.32360
This article is protected by copyright. All rights reserved
DR. SAMILIA  OBENG-GYASI (Orcid ID : 0000-0002-5330-7247)
MR. BENJAMIN J KEELE (Orcid ID : 0000-0002-6029-6785)
DR. LYNNE  WAGNER (Orcid ID : 0000-0001-9685-4796)
DR. RUTH  CARLOS (Orcid ID : 0000-0001-7055-7662)
Article type      : Commentary
Oncology Clinical Trials and Insurance Coverage: An Update in a Tenuous Insurance 
Landscape
Running Title: Insurance and clinical trials
Samilia Obeng-Gyasi1, Sheetal M. Kircher2, Kelsey P Lipking1, Benjamin J. Keele3, Al B. 
Benson2, Lynne I Wagner4, Ruth C. Carlos5 
1. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, 
USA
3.  Indiana University Robert H. McKinney School of Law, Indianapolis, IN, USA
4. Social Sciences & Health Policy Comprehensive Cancer Center, Wake Forest School of 
Medicine, Winston-Salem, NC, USA.


















This article is protected by copyright. All rights reserved
Samilia Obeng-Gyasi





Funding: The research reported in this publication was supported in part by the National 
Cancer Institute of the National Institutes of Health through ECOG-ACRIN under award 
numbers UG1CA189828 and U10CA180820. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the National Institutes of Health 
nor ECOG-ACRIN. 
Conflict of Interest: Please see completed conflict of interest forms. 
Acknowledgements: none
Precis: The heterogeneous state and federal insurance laws for oncology clinical trial coverage 
are confusing for healthcare providers, patients and other stakeholders.  There needs to be 
clearer explication and education about clinical trial coverage to help improve patient access.
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Introduction
Clinical trials are a crucial component in the advancement of cancer treatment and 
cancer care. However, enrollment in clinical trials continue to lag due to multiple variables 
including insurance-based disparities in coverage.1-6 At the level of the healthcare system, lack 
of provider knowledge and inconsistent support or initiation of a discussion about clinical trials 
impede accrual.7,8 The poor enrollment growth is worrisome as studies have shown increased 
survival among participants of oncologic clinical trials compared to their non-clinical trial 
counterparts.9,10  Furthermore, a study evaluating life years gained through participation in 
Southwest Oncology Group (SWOG) clinical trials revealed a 3.34 million life years gain and a 
$125 return on investment per life year gained.11  Nevertheless, despite the remarkable 
progress in cancer treatment secondary to clinical trials, insurance coverage has remained a 
barrier for enrollment.3,12
As federal legislators seek to change key components of the ACA and state legislators 
fine-tune requirements for enrollment and participation in Medicaid, it is important to gain an 
understanding of the current insurance landscape for coverage of oncology clinical trials. To this 
end, the objective of this review is to present a current overview of federal and state laws, 
regulations and agreements on insurance coverage for oncology clinical trials. In addition, we 
seek to understand the initiation and extent of state laws for private insurers on clinical trial 
coverage to better understand how patient access to clinical trials maybe affected by repealing 
the current ACA statute requiring coverage.
Methods
To identify summaries of state and federal law(s) on oncology clinical trial coverage we 
used Westlaw to identify the current statues, regulations and agreements on clinical trial 
coverage for private insurers and Medicaid for each state and the District of Columbia. Westlaw 
was queried with the keywords--clinical trials and insurance. Subsequently, the statute number, 
date of enactment, effective dates and services covered were aggregated into a table. 
Medicare and Oncology Clinical Trial Coverage
Since the enactment of Medicare and Medicaid in 1965, there have been numerous 
amendments that have expanded the scope and coverage of these government programs. For 
patients over the age of 65 enrollment in oncology clinical trials have been low compared to 
their younger counterparts13,14. The age-based disparity in oncology clinical trial enrollment is 
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participation include a multifactorial interplay of physician, patient and trial related barriers.16  To 
help address this issue, in 2001 former President Clinton directed the federal Medicare program 
to issue a special National Coverage Determination (NCD) that authorized payments for the 
costs of routine care and research-related complications for clinical trials.17 The NCD has 
specific regulations regarding what is included in “routine costs” and only trials with therapeutic 
intent are included; thus, excluding most Phase I and many Phase II studies.  Implementation of 
the NCD made noticeable progress in improving enrollment of Medicare aged patients to 
oncology trials.  Specifically, Unger et al’s study evaluating enrollment of Medicare-aged 
patients in clinical trials showed a 13% increase in enrollment among the Medicare population to 
SWOG trials three years from the inception of the NCD.15,18 However, the NCD still left 
unaddressed, the coverage concerns of the roughly 86% of the population not covered by 
Medicare.19
Medicaid and Oncology Clinical Trial Coverage
Although the ACA addresses oncology clinical trial coverage by private insurers, it 
leaves coverage under Medicaid up to the states. Currently, only 10 states and the District of 
Columbia (DC) require Medicaid to cover the routine cost of clinical trials (Table 1). Conversely, 
39 states exclude the coverage of clinical trials in their scope of services and/or pharmacy billing 
services for Medicaid. All the states with coverage of clinical trials through Medicaid have 
enactment and effective dates prior to the enactment of the ACA. In our search of their scope of 
services under Medicaid, Pennsylvania appeared unclear about the coverage of clinical trials. 
Interestingly, among the states requiring Medicaid coverage for clinical trials, Alaska, California, 
Indiana, Iowa, Maryland, Montana, Vermont, West Virginia, and DC participated in the Medicaid 
expansion under the ACA. On the other hand, despite having laws for clinical trial coverage 
through Medicaid, Texas and North Carolina elected to not implement the ACA Medicaid 
expansion. 
The heterogeneity of Medicaid coverage for clinical trials across states warrants further 
evaluation as multiple studies have shown an association between lower socioeconomic status 
and late disease presentation.20-22 Specifically, Medicaid patients with breast, cervical, colorectal 
and prostate cancer are more likely to present with a later disease stage than their privately 
insured counterparts. 23-29  Due to their late disease presentation and worse survival, this 
population may benefit from increased access to clinical trials through Medicaid as they have 
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The ACA and Oncology Clinical Trial Coverage
Prior to passage of The Patient Protection and Affordable Care Act (ACA), private 
insurers were reluctant to cover any cost associated with a clinical trial despite reports that the 
incremental cost increase for trial participation was 10% or less.30-32 The ACA is the first federal 
law requiring private insurers to cover the routine cost of clinical trials under section 2709. 33 
The law stipulates  “[the] clinical trial is conducted in relation to the prevention, detection, or 
treatment of cancer or other life-threating disease or condition.”34 As a result of the ACA, 
individuals with “group health plan[s], a health insurance issuer in the group and individual 
health insurance market [plans]” can elect to participate in clinical trials provided they meet the 
trial’s eligibility criteria.35  
Health plans covered by the Employee Retirement Income Security Act (ERISA) are also 
required to adhere to the ACA clinical trial coverage guidelines as these plans are bound by 
federal laws.33 Under the law, insurers cannot deny coverage for diagnostic imaging, laboratory 
test or procedures considered standard of care because of patient participation in clinical trials. 
This is noteworthy as in 2010 only 18 states met the clinical trial coverage requirements 
currently outlined in the ACA.36 Approved trials include phases I, II, III or IV clinical trials that are 
federally funded, FDA approved Investigational New Drugs (IND) or IND application exempt 
drugs.37 
Although the ACA law increases access to oncology clinical trials, grandfathered plans 
and Medicaid are not required to cover the cost of clinical trials.38 The ACA describes 
grandfathered plans as plans with current coverage guidelines that precede the March 27, 2013 
enactment of the ACA. In order to maintain their grandfathered status, these plans cannot make 
significant changes to coverage, benefits or cost sharing.36,39 This loophole in coverage is 
notable as studies have shown an association between insurance-based barriers and clinical 
trial enrollment.40-42 In the 2016 Employer Health Benefits Survey by the Kaiser Foundation, 
23% of firms reported at least one grandfathered plan.  Furthermore, 23% of employees in the 
survey were enrolled in grandfathered plans.43  
Due to its recent implementation, the effects of the ACA on oncology clinical trial 
coverage and subsequent enrollment is still evolving. An examination of clinical trial coverage in 
Kansas among adults aged 19-64 projected a 3% increase in clinical trial coverage under the 
ACA.44 In their institutional review of large early phase cancer clinical trials, Kehl et al noted 
improved insurance clearance rates among the privately insured post ACA.45 However, a survey 
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barriers to clinical trials with denials of coverage or delays.  Grandfathered plans, out of network 
providers/sites and claims by insurers that they do not cover clinical trial, were the most 
common reasons for denial of coverage.46 These findings indicate that there might be some 
misperception among insurers and healthcare providers about clinical trial coverage under the 
ACA. This issue is further compounded by confusion on the part of employers about the 
grandfathered status of their health plans.43 
State Statutes and Private Insurer Coverage for Oncology Clinical Trials
Only 33 states and the District of Columbia had enacted statutes or regulations requiring 
private insurance coverage for the routine cost of clinical trials prior to the ACA marketplace 
insurance going into effect on January 1st, 2014 (Table 2). Though they do not have statutes 
addressing coverage of clinical trials, Florida, Georgia, Michigan, Nebraska, New Jersey and 
South Carolina have agreements with private insurers for coverage of the routine cost of care 
associated with clinical trials. Currently based on our search of Westlaw 11 states have no laws 
or agreements with private insurers requiring clinical trial coverage.  
There are considerable differences in the type and phase of private insurer clinical trial 
coverage by states (Table 3). Some states only cover specific phases of oncology clinical trials. 
For example, statutes in Illinois, Louisiana, Missouri, Nevada, West Virginia and Wyoming do 
not cover phase I clinical trials.  Discrepancies in phases of clinical trial coverage by state is 
significant as it indicates differences in access to clinical trials based on state. The ACA law 
remedies this disparity because it requires private insurers to cover all phases of clinical trials. 
Moreover, the ACA is a federal law which consequently supersedes current state law. To this 
end, significant changes to the ACA resulting in a repeal of insurance coverage, as currently 
outlined, would exacerbate state level disparities in access to clinical trials among the privately 
insured. Specifically, patients in states with limited coverage of all phases of oncology clinical 
trials may experience a reduction in access to phase I or II clinical trials. 
Future Directions
As significant progress is made in cancer care delivery, it is important to ensure that all 
patients have access to cutting edge treatments.  Our review of Medicaid, Medicare, the ACA 
and state law for private insurance has shown that there are significant legislative gaps in 
coverage for oncology clinical trials.  A repeal of the clinical trial coverage component of the 
ACA may reduce access to phase I and II clinical trials among privately insured individuals in 
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adequately required to cover oncology clinical trials resulting in a coverage gap for individuals 
who fall into those groups. To help alleviate some of the legislative discrepancies in coverage 
we propose the following recommendations (Figure 1): 1) remove the exclusion of the 
grandfather clause in the Affordable Care Act, 2) require Medicaid in all states to cover the 
routine cost of care associated with oncology clinical trials, 3) require all states to have 
legislation requiring private insurers to cover oncology clinical trials independent of the federal 
ACA law.
With the Tax Cuts and Jobs Act of 2017 eliminating the tax penalty for lack of insurance, 
we anticipate there will be continued changes in access to oncology clinical trials as individuals 
make decisions about their insurance status. Furthermore, a recent correspondence to the New 
England Journal of Medicine by Sommers et al reveal a 20% reduction in ACA coverage gains 
between 2013 and 2016 under the Trump administration.47 With these continued changes to 
components of the ACA, patients, healthcare providers and healthcare stakeholders will need 
clearer education about insurance coverage for clinical trials. 
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Table 1: States with Medicaid Coverage for Oncology Clinical Trials 
 






Alaska Alaska Stat. § 
21.42.415 
7/1/2010 7/1/2010 





D.C. Code § 31-
2993.02 
6/5/2008 6/5/2008 
Indiana Ind. Code § 27-8-25-
8 
5/7/2009 6/30/2009 
Iowa Iowa Code § 514C.26 2/23/2010 7/1/2010 
Maryland MD Code, Ins. § 15-
827 
4/28/1998 1/1/1999 





N.C. Gen. Stat. § 
58-3-255 
10/18/2001 3/1/2002 
Texas Tex. Ins. Code § 
1379.052 
6/19/2009 9/1/2009 
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Alabama No         
Alaska Yes Alaska Stat. § 21.42.415 statute 7/1/2010 9/29/2010 




Arkansas No         
California Yes Cal. Ins. Code § 10145.4 statute 8/9/2001 1/1/2003 








Delaware Yes Del. Code tit. 18, § 3351 statute 6/25/2002 7/1/2002 
District of 
Columbia 
Yes D.C. Code § 31-2993.02 statute 6/5/2008 
6/5/2008 
Florida Yes   agreement 7/1/2010 7/1/2010 
Georgia Yes   agreement 2002 2002 
Hawaii No         
Idaho No         




Indiana Yes Ind. Code § 27-8-25-8 statute 5/7/2009 7/1/2009 
Iowa Yes Iowa Code § 514C.26 statute 2/23/2010 7/1/2010 








Louisiana Yes La. Stat. § 22:1044 statute 7/12/1999 7/12/1999 
Maine Yes Me. Stat. tit. 24, § 4310 statute 1999 1999 
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Michigan Yes   agreement 6/6/2001 6/6/2001 
Minnesota Yes Minn. Stat.§ 62Q.526 statute 5/21/2013 1/1/2014 
Mississippi No         
Missouri Yes Mo. Rev. Stat. § 376.429 statute 7/2/2002 7/6/2006 
Montana Yes Mont. Code § 33-22-153 statute 3/27/2013 3/27/2013 
Nebraska Yes   agreement 11/1/2009 11/1/2009 




New Hampshire Yes N.H. Rev. Stat. § 415:18-l statute 6/12/2000 1/1/2001 
New Jersey Yes   agreement 2/16/2000 2/16/2000 
New Mexico Yes N.M. Stat. § 59A-22-43 statute 3/14/2001 3/14/2001 
New York No         
North 
Carolina 
Yes N.C. Gen. Stat. § 58-3-255 statute 10/18/2001 
3/1/2002 
North Dakota No         
Ohio Yes Ohio Rev. Code § 3923.80 statute 5/6/2009 8/4/2008 
Oklahoma No         
Oregon Yes Or. Rev. Stat. § 743A.192 statute 6/16/2009 1/1/2010 
Pennsylvania No         
Rhode Island Yes R.I. Gen. Laws § 27-18-74 statute 6/18/2012 1/1/1995 
South 
Carolina 
Yes   agreement 7/1/2010 
7/1/2010 
South Dakota No         
Tennessee Yes Tenn. Code § 56-7-2365 statute 5/26/2005 7/1/2005 
Texas Yes Tex. Ins. Code § 1379.052 statute 6/19/2009 9/1/2009 
Utah No         
Vermont Yes Vt. Stat. tit. 8, § 4088b statute 4/26/2001 4/26/2001 
Virginia Yes  Va. Code § 38.2-3418.8 statute 3/28/1999 7/1/2000 




West Virginia Yes W. Va. Code § 33-25F-2 statute 3/8/2003 6/8/2003 
Wisconsin Yes Wis. Stat. § 632.87 statute 3/24/2006 11/1/2006 
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Table 3: Details of Private Insurer Oncology Clinical Trial Coverage by State* 
 
State Coverage Details Coverage of Cancer 
Trials Only† 
Alaska no limit yes 
Arizona I, II, III, IV yes 
California I, II, III, IV yes 
Colorado no limit no 
Connecticut phase III, until limit 
removed 7-13-2011 
yes, until limit 
removed 7-13-2011 
DC no limit no 
Delaware no limit no 
Illinois II, III, IV yes 
Indiana no limit no 
Iowa no limit yes 
Kansas I, II, III, IV yes 
Kentucky no limit yes 
Louisiana II, III, IV yes 
Maine no limit no 
Maryland I, II, III, IV no 
Massachusetts I, II, III, IV yes 
Minnesota I, II, III, IV no 
Missouri II, III, IV yes 
Montana I, II, III, IV yes 
Nevada II, III, IV yes 
New Hampshire III, IV, case-by-case for 
I, II 
no 
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Ohio no limit yes 
Oregon no limit no 
Rhode Island I, II, III, IV no 
Tennessee I, II, III, IV yes 
Texas I, II, III, IV no 
Vermont no limit yes 
Virginia II, III, IV, case-by-case 
for I 
yes 
Washington I, II, III, IV no 
West Virginia II, III, IV no 
Wisconsin no limit yes 
Wyoming II, III, IV yes 
*Unfortunately, our review of the agreements for Florida, Georgia, Michigan, New Jersey, Nebraska, and South Carolina did not 
reveal any relevant information about the details of clinical trial coverage; as a result, they were omitted from Table 3.  















Figure 1: Recommendations to address disparities in insurance coverage for oncology clinical 
trials 
 
1. Remove the exclusion of the grandfather clause in the Affordable Care Act. 
2. Require Medicaid in all states to cover the routine cost of care associated with 
oncology clinical trials. 
3. Require all states to have legislation requiring private insurers to cover oncology 
clinical trials independent of the federal ACA law. 
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